PepGen, Inc. (NASDAQ:PEPG - Free Report) - Equities researchers at HC Wainwright dropped their FY2026 EPS estimates for shares of PepGen in a note issued to investors on Monday, November 16th. HC Wainwright analyst A. Ghosh now expects that the company will post earnings per share of ($1.09) for the year, down from their prior forecast of ($1.03). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for PepGen's current full-year earnings is ($1.13) per share. HC Wainwright also issued estimates for PepGen's Q4 2026 earnings at ($0.29) EPS, Q1 2027 earnings at ($0.29) EPS, Q2 2027 earnings at ($0.30) EPS, Q3 2027 earnings at ($0.30) EPS, Q4 2027 earnings at ($0.32) EPS, FY2027 earnings at ($1.21) EPS, FY2028 earnings at ($1.06) EPS, FY2029 earnings at ($0.88) EPS and FY2030 earnings at ($0.40) EPS.
PEPG has been the topic of several other research reports. Bank of America upgraded shares of PepGen from an "underperform" rating to a "neutral" rating and raised their price target for the company from $2.50 to $6.00 in a research report on Tuesday, November 10th. Wall Street Zen downgraded shares of PepGen from a "hold" rating to a "sell" rating in a research report on Sunday. Guggenheim upped their price objective on shares of PepGen from $7.00 to $15.00 and gave the stock a "buy" rating in a research report on Friday, November 13th. Wedbush increased their target price on shares of PepGen from $4.00 to $10.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 11th. Finally, Weiss Ratings raised shares of PepGen from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, September 22nd. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $11.40.
Read Our Latest Stock Report on PepGen
PepGen Stock Performance
Shares of NASDAQ PEPG opened at $3.88 on Wednesday. The company's fifty day moving average price is $2.83 and its 200 day moving average price is $2.96. PepGen has a 1 year low of $1.31 and a 1 year high of $7.80. The company has a market capitalization of $268.73 million, a PE ratio of -3.63 and a beta of 2.02.
PepGen (NASDAQ:PEPG - Get Free Report) last posted its earnings results on Tuesday, November 10th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.01).
Institutional Trading of PepGen
A number of institutional investors and hedge funds have recently made changes to their positions in PEPG. Squarepoint Ops LLC increased its holdings in PepGen by 260.9% in the 2nd quarter. Squarepoint Ops LLC now owns 529,083 shares of the company's stock worth $952,000 after acquiring an additional 382,487 shares in the last quarter. ADAR1 Capital Management LLC acquired a new position in PepGen during the second quarter worth $4,664,000. GSA Capital Partners LLP purchased a new position in PepGen during the second quarter valued at $1,535,000. BlackRock Inc. purchased a new position in PepGen during the second quarter valued at $2,348,000. Finally, Kalehua Capital Management LLC purchased a new position in PepGen during the first quarter valued at $1,770,000. 58.01% of the stock is currently owned by hedge funds and other institutional investors.
Key PepGen News
Here's some of the latest news about PEPG:
- Positive Sentiment: HC Wainwright raised its projected earnings for FY2027 through FY2030, forecasting losses that narrow from $1.21 per share in FY2027 to $0.40 in FY2030. The analyst also retained a Buy rating, offering a more favorable longer-term outlook. PepGen analyst estimates
- Negative Sentiment: Near-term forecasts were cut: the Q4 2026 loss estimate worsened to $0.29 per share from $0.26, and the FY2026 estimate moved to a $1.09 loss from $1.03. These revisions point to higher expected losses in the nearer term. PepGen analyst estimates
PepGen Company Profile
(
Get Free Report)
PepGen is a clinical-stage biotechnology company developing oligonucleotide medicines for people with neuromuscular diseases. Its Enhanced Delivery Oligonucleotide (EDO) platform is designed to help deliver these medicines to muscle tissue. The company's pipeline includes PGN-EDO51, an investigational exon-skipping therapy for Duchenne muscular dystrophy in patients whose genetic mutations are amenable to exon 51 skipping, and PGN-EDODM1, an investigational candidate for myotonic dystrophy type 1.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider PepGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PepGen wasn't on the list.
While PepGen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.